

AFOSR

TR-77-0865

FC

FINAL REPORT

15, VAF-77-2780-2781-75

Air Force Grant AFOSR-75-2780

12

14 USC-53-5137-1775

AD A 038349

6

The Contribution of Vascular Receptors to +Gz Tolerance,

January 1, 1975 through November 30, 1975

Final Scientific Report, 1 Jan - 1 Nov 75, 1
Submitted to

Department of the Air Force
Air Force Office of Scientific Research
Bolling Air Force Base
Building 410
Washington, D.C. 20332

By

Department of Physiology
University of Southern California
School of Medicine
2025 Zonal Avenue
Los Angeles, California 90033

DDC
APR 15 1977
RECEIVED
C

Principal Investigators

10 Christopher M. Stevens, M.D.
Assistant Professor
Department of Physiology
(213) 226-2245

Roland D. Rader, Ph.D.
Research Director
Department of Physiology
(213) 746-2347

11 p Nov 51

Approved for the Department of Physiology

12 b6 p.

J.P. Meehan
John P. Meehan, M.D.
Professor and Chairman

Approved for public release;
distribution unlimited.

4-5 147 CS

AD No. DDIC FILE COPY

AIR FORCE OFFICE OF SCIENTIFIC RESEARCH (AFSC)
NOTICE OF TRANSMITTAL TO DDC

This technical report has been reviewed and is
approved for public release IAW AFR 190-12 (7b).
Distribution is unlimited.

A. D. BLOSE
Technical Information Officer

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER AFOSR - TR - 77 - 0365 ✓	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (and Subtitle) THE CONTRIBUTION OF VASCULAR RECEPTORS TO +Gz TOLERANCE ✓		5. TYPE OF REPORT & PERIOD COVERED Final Scientific Report 1 Jan 75 - 30 Nov 75
		6. PERFORMING ORG. REPORT NUMBER
7. AUTHOR(s) Christopher M. Stevens Roland D. Rader		8. CONTRACT OR GRANT NUMBER(s) AFOSR-75-2780 <i>NEW</i>
9. PERFORMING ORGANIZATION NAME AND ADDRESS University of Southern California Department of Physiology ✓ Los Angeles, California 90033		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS 61102F 9777-02
11. CONTROLLING OFFICE NAME AND ADDRESS Air Force Office of Scientific Research (NL) Bolling AFB DC 20332		12. REPORT DATE 30 November 1975
		13. NUMBER OF PAGES 62
14. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		15. SECURITY CLASS. (of this report) Unclassified
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report) Approve for public release; distribution unlimited.		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number)		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The feasibility of employing instrumental, restrained, conscious dogs in acceleration studies on the centrifuge has been demonstrated. The leads from implanted sensors pass through the skin on the upper back and when not connected to signal conditioning equipment are placed in a pocket of a nylon jacket worn by the dog. Protection of the sensor leads, in addition to the jacket, is afforded by an inflated rubber tube placed about the dog's neck. Measurements of carotid artery flow, vena caval flow and aortic pressure have		

20. been obtained during experimental sequences. The investigators felt that the primary effect of denervation was attenuation of peripheral resistance to rapid onset acceleration necessitating significantly higher heart rates and cardiac outputs for a given carotid flow and eye level blood pressure.



INTRODUCTION

Investigation of mammalian cardiovascular regulatory mechanisms have demonstrated the existence of both high pressure and low pressure receptor systems which provide information to the central regulatory centers concerning the hemodynamic status of the heart and circulation (1,2,3,6,7). In addition to the well known sinoaortic baroreceptor systems, there are intracardiac receptors located in the atria and in the ventricles which influence heart rate and peripheral vascular tone. When man is exposed to acceleration in excess of the 1 G experienced normally, the distribution of his circulating blood volume may be altered. The +Gz acceleration forces are particularly effective in pooling blood in dependent vascular beds, resulting in a diminution of blood flow to the brain and venous inflow to the heart from dependent vascular beds. The response of the cardiovascular system to this gravitational stress depends on afferent information received from both the high and low pressure receptor systems (4,5,8,9). Previous studies of the operation of these receptor mechanisms under increased acceleration loading have been primarily conducted under slowly developing G forces under specific levels of acceleration maintained for relatively brief periods. However, the aircrew in a high performance fighter aircraft is exposed to acceleration forces which are cyclic and rapidly changing in both magnitude and direction over relatively long periods of time. Information relating to response times, relative magnitude of response, specificity of response, and fatigue of response would

aid in the evaluation of aircrew performance in a rapidly changing +G environment as is encountered in modern fighter aircraft.

A. Three-Year Plan

The principal objective of the proposed three-year research plan was to investigate these factors in a conscious dog by assessing the contributions of the carotid sinus, the aortic arch, and the cardiac mechanoreceptor (baroreceptor) mechanisms to the maintenance of cerebral blood flow and venous inflow to the heart during exposure to the +Gz acceleration profiles simulating high performance jet aircraft air combat maneuvers. The original investigation was designed to (1) characterize the normal cardiovascular responses to cyclic +Gz exposure on the centrifuge in terms of carotid blood flow, head-level arterial blood pressure, inferior vena caval flow, central venous and/or right atrial pressure, electrocardiograms, and arterial oxygen saturation in the adult dog and adult miniature swine; (2) analyze the specific contribution of each receptor area to the normal response through the study of experimental subjects with denervated receptor areas; (3) assess the possible effects of fatigue and habituation of the receptor on the magnitude of the cardiovascular "antigravity" responses; and (4) contrast responses obtained with and without an antigravity suit.

B. Sixteen-Month Performance Program

Various factors precluded the opportunity to complete the three-year plan as outlined in the work statement. The first year's effort called for data acquisition from 6 dogs, 3 with carotid sinus denervation and 3 with aortic baroreceptor denervation. Data were actually acquired from 5 dogs with the support received for the first 12-month effort. One dog served as a test case to develop acceleration levels, restraint systems, and data acquisition methods. Data were obtained from 1 dog with both carotid sinus and aortic baroreceptor denervation, from 2 dogs with carotid sinus denervation, and from all 5 dogs prior to any denervation. An antigravity suit was used on 2 dogs.

METHODS

This investigation required the degree of impairment in +Gz tolerance of instrumented dogs to be evaluated on the basis of flow and pressure responses to a set of acceleration profiles before and after cardiovascular areas were selectively denervated. By a procedure of surgical denervation of the carotid sinus receptor areas, a determination of the contribution of these specific areas to the maintenance of +Gz tolerance in the experimental subjects was made. The analysis of alteration in response time, magnitude of the response, specificity of the response, and fatigue of the remaining functional cardiovascular receptor areas was determined with and without an antigravity suit by assessing changes in carotid arterial flow, head-level arterial pressure, and venous inflow to the heart.

A. Instrumentation

Flow in the common carotid arteries and in the thoracic vena cava was measured by the use of chronically implanted flow probes. The phase difference between brief pulses of ultrasonic energy transmitted simultaneously from a pair of barium titanate crystals diagonally through the vessel was used as the basic measurement of volumetric blood flow (11). Calibration was conducted before implantation by forcing fluid through the probe lumen and measuring the output voltage from the meter as a function of the quantity of flow. Central arterial pressure was measured with a small button-type transducer implanted in the thoracic aorta. The techniques of implantation and calibration have been presented elsewhere (10).

B. Profiles

The acceleration profiles used in this study were developed from an actual ACM profile obtained from the F-4-E fighter aircraft. This profile was scaled to the +Gz tolerance of the dog, using head-level arterial pressure and carotid blood flow as criteria for the determination of peripheral light loss (PLL) and central light loss (CLL). The profiles which were developed for conscious dogs are shown in Figure 1. These profiles consisted of (1) an ACM scaled to a peak of $4 + Gz$, (2) a 5-cycle pulse to a peak level of $4 + Gz$ and a sustained $2.5 + Gz$ which was the mean level of the ACM profile.

Figure 2 illustrates the dog and the rider on the centrifuge. The tolerance and the availability of riders became a limiting factor in the data acquisition, so the requirement for the rider was eliminated






Figure 1






Figure 3

through the use of a special harness designed to restrain the dog's head (Fig. 3). With this improvement, fatiguing of the dog became the limit on data acquisition.

C. Surgical Procedures

Instrumentation Implant

Surgical implantation of the blood flow and pressure sensors was performed in two successive procedures. The subjects were preoperatively medicated with 1/150 gr atropine sulfate and 75 mg Demerol. Anesthesia was induced with sodium thiamylal and the subjects were then intubated and anesthesia maintained, using halothane and oxygen. In the first procedure, blood flow sensors were placed bilaterally on the common carotid arteries and the sensor cables were led subcutaneously to the dorsum, medial to the scapulae. The subjects were given 600,000 units of aqueous penicillin G daily for 5 days postoperatively. After 7 to 10 days, the subjects were anesthetized again and a left thoracotomy was performed through the 5th intercostal space and a blood flow sensor was placed around the inferior vena cava. A solid state intravascular pressure transducer was then placed in the descending aorta at the level of the atrioventricular ring. These sensor cables were also led subcutaneously to the same region of the dorsum and the above postoperative regimen was performed.

After a sensor grow-in period of 21 to 30 days, the subjects were again anesthetized and the sensor connectors were exteriorized and placed in a pocket of the jacket worn by the experimental subject.

Denervation Procedures

The subjects were anesthetized and the carotid sinus exposed. The carotid sinus nerves were sectioned and the animals were allowed to recover for 5 to 7 days.

Aortic baroreceptor denervation was performed via a left thoracotomy through the 4th intercostal space. A recovery period of 14 to 21 days was allowed after aortic baroreceptor denervation.

D. Data Acquisition and Reduction

Preamplifiers for acceleration, pressure, and flow measurements were placed on the centrifuge near the location of the dog. The basic signals were conditioned and increased to an approximately 1-volt level. These signals were connected to a strip chart recorder through slip rings. Mean levels of the basic flow and pressure signal were obtained by electronic integration and displayed on the strip chart recorder. Data reduction consisted of charting mean levels of flow pressure and heart rate at particular points throughout the acceleration profiles. Analysis was made in terms of the percent change from control at each of the selected conditions of antigravity suit protection, denervation, and acceleration. The data were then analyzed for standard deviation and standard error of the mean.

E. Antigravity Protection

A modified abdominal bladder from a standard anti-G suit was used in conjunction with an Alar Products Inc. Automatic Pressure Regulating Anti-G Suit Valve to afford antigravity protection for the subjects. Figures 4, 5, and 6 illustrate the pressure responses of the above system




Figure 4

4.0 + Gz PULSE PROFILE




Figure 5




Figure 6

during the 4 + Gz ACM, the 4 + Gz Pulse, and the 2.5 + Gz Sustained Acceleration Profiles, respectively. The subjects were exposed to the three acceleration profiles with and without antigravity protection.

RESULTS

Data were obtained from five dogs during the course of this study with the first subject (Dog B) being used primarily for the development of acceleration profiles and the scaling of these profiles to the dog's acceleration tolerance. In addition, it became necessary to further develop an animal restraint system for the dogs to eliminate the need for an investigator to ride with the conscious subject. Consequently, Dog B was used for the further development of the restraint system. Results obtained from these preliminary studies on Dog B are not presented, since the acceleration profiles employed were variable both in magnitude of acceleration and in duration of exposure.

A. 4.0 + Gz ACM Profile Exposures

Control and carotid sinus denervation data obtained from Dog A and Dog L during exposure to the 4.0 + Gz ACM with and without antigravity protection are shown in Tables 1-4 and in Figures 7-19, and control data for Dog D and Dog M are shown in Tables 5 and 6 and in Figures 20-22. Figures 23-32 show the comparison between the control response and the response obtained after carotid sinus denervation in Dog A with and without antigravity protection and in Dog L without antigravity protection.

B. 4.0 + Gz Pulse Profile Exposures

Control and carotid sinus denervation data obtained from Dog A and Dog L during exposure to the 5-cycle 4.0 + Pulse Profile with and without antigravity protection are shown in Tables 7-10 and data obtained from Dog D and Dog M without antigravity protection are shown in Tables 11 and 12.

C. 2.5 + Gz Sustained Profile

Control and carotid sinus denervation data obtained from Dog A and Dog L during exposure to the 2.5 + Sustained Profile with and without antigravity protection are shown in Tables 13-16 and data obtained from Dog D and Dog M without antigravity protection are shown in Tables 17 and 18.

DISCUSSION

The control responses obtained during exposure to the 4.0 + Gz ACM Profile consisted of an average decrease in carotid flow of 20% below normal, and there was no apparent overall significant difference between the Control Group and the carotid sinus denervation group (Group A). Central arterial pressure in the Control Group rose to an average of 30% above normal, while the average pressure in Group A was 25% above normal. The major distinction between the Control Group and Group A appeared in the heart rate response required to maintain central arterial pressure and carotid arterial flow. The heart rate in the Control Group averaged 24% above normal, while in Group A the average rate was 74% above normal.

Exposure to the 4.0 + Gz Pulse Profile resulted in an average decrease in carotid blood flow of 49% at the 4.0 + Gz peaks in the Control Group and a decrease of 66% in Group A. Central arterial pressure at the 4.0 + Gz peak was increased 19% in the Control Group and 2% in Group A, while eye level pressure decreased 90% in the Control Group and 100% in Group A at the 4.0 + Gz peak. Average heart rates at the 4.0 + Gz peaks increased by 89% in the controls and by 141% in Group A.

Exposure to the 2.5 + Gz Sustained Profile resulted in an average decrease in carotid blood flow of 20% in both the Control Group and in Group A. Central arterial pressure was increased 20% above normal in the Control Group and 10% above normal in Group A. Eye level mean blood pressures decreased 35% below normal in the Control Group and 50% below normal in Group A. Heart rates increased an average of 40% above normal in the Control Group and 55% above normal in Group A.

The use of the antigravity suit abdominal bladder assisted in maintaining the carotid flow and eye level arterial pressure in both the control and denervated groups. The effect of the suit during exposure to all profiles was to create a condition where for a given level of carotid blood flow the heart rate was significantly lower and the central and eye level blood pressures were significantly higher than in the unprotected state. The most pronounced decrement in the ability to maintain carotid flow produced by carotid sinus denervation was in the environment where

the rate of onset of the acceleration forces was the greatest. Further, denervation resulted in a lower central and eye level arterial pressure despite a greatly elevated heart rate. It was felt that the primary effect on cardiovascular hemodynamics of the denervation was to attenuate the expected peripheral resistance changes to rapid onset acceleration, thus necessitating significantly higher heart rates and probably cardiac outputs for a given carotid flow and eye level blood pressure.

TABLE I

ACM PROFILE
 NO G-SUIT
 SUBJECT: DOG A

()=Sx

+Gz	Level	1.0	2.5	2.0	3.0	2.0	4.0	2.5	3.5	2.5	3.0	1.0	STOP	n
CAROTID FLOW	CONT	83.7 (3.4)	66.4 (4.0)	55.3 (7.2)	37.9 (8.9)	61.7 (8.4)	14.6 (5.0)	38.7 (7.2)	31.4 (9.6)	53.5 (11.1)	46.3 (12.1)	90.5 (6.6)	116.9 (7.8)	6
	C/S DEN													
VENA CAVA FLOW	CONT	90.2 (1.4)	73.6 (3.6)	75.8 (2.2)	76.1 (2.7)	76.6 (3.5)	73.4 (2.1)	76.2 (4.1)	75.3 (2.8)	74.5 (2.8)	77.9 (2.9)	80.5 (2.4)	106.5 (5.1)	11
	C/S DEN	126.9 (9.1)	103.3 (6.1)	115.3 (3.3)	107.9 (4.9)	115.1 (3.7)	92.4 (10.5)	103.7 (3.1)	102.6 (6.4)	103.1 (6.6)	99.3 (4.2)	152.8 (7.9)	163.5 (7.9)	7
CENTRAL ARTERIAL PRESSURE	CONT	109.2 (1.2)	118.5 (3.2)	116.9 (2.1)	131.0 (2.9)	120.0 (2.0)	136.0 (4.5)	132.1 (3.2)	138.4 (3.5)	132.2 (3.4)	138.6 (3.5)	80.5 (2.4)	106.5 (5.1)	26
	C/S DEN	143.1 (6.1)	165.1 (4.7)	159.1 (3.7)	190.0 (5.6)	165.6 (2.5)	219.7 (7.5)	200.4 (5.9)	223.0 (7.9)	199.7 (6.3)	216.9 (5.6)	154.7 (6.4)	138.3 (9.5)	7
EYE LEVEL PRESSURE	CONT	87.2	64.5	72.9	66.0	76.0	49.0	78.1	62.4	78.2	73.6	89.0	107.2	26
	C/S DEN	94.1	43.1	61.1	43.0	71.0	23.7	78.4	52.0	77.7	69.9	105.7	138.3	7
HEART RATE	CONT	136.4 (4.9)	157.4 (8.1)	135.4 (6.1)	153.6 (8.1)	142.6 (10.1)	152.6 (10.7)	145.9 (8.0)	152.2 (8.9)	150.1 (7.4)	150.5 (7.4)	156.6 (8.7)	123.6 (4.2)	26
	C/S DEN	119.4 (7.7)	134.1 (10.9)	117.6 (10.2)	119.3 (10.2)	101.7 (16.5)	123.6 (6.3)	121.3 (9.2)	140.3 (6.6)	124.9 (13.9)	135.7 (11.7)	168.1 (6.8)	151.0 (11.0)	7

TABLE 2

ACM PROFILE
G-SUIT

SUBJECT: DOG A

() = S \bar{x}

+Gz	LEVEL	1.0	2.5	2.0	3.0	4.0	2.5	3.5	2.5	3.0	1.0	STOP	n
CAROTID FLOW	CONT	101.3 (11.1)	82.3 (5.7)	78.6 (10.4)	52.4 (5.6)	60.8 (5.4)	35.8 (11.9)	21.6 (9.8)	41.0 (9.5)	28.1 (10.2)	106.9 (11.2)	143.4 (16.3)	7
	C/S DEN												
VENA CAVA FLOW	CONT	103.5 (6.0)	97.5 (7.2)	94.3 (4.0)	87.3 (7.2)	91.5 (5.3)	91.3 (2.9)	83.3 (4.0)	89.5 (6.0)	86.8 (4.9)	97.5 (6.7)	101.5 (1.5)	4
	C/S DEN	146.8 (7.2)	141.0 (6.8)	121.6 (8.0)	100.2 (13.0)	122.0 (7.3)	90.8 (8.3)	67.2 (9.3)	96.6 (8.1)	80.4 (9.5)	147.4 (13.4)	159.4 (8.9)	5
CENTRAL ARTERIAL PRESSURE	CONT	113.4 (0.9)	133.4 (1.8)	127.8 (1.2)	145.1 (1.6)	134.3 (2.5)	147.3 (3.1)	155.8 (2.5)	148.3 (2.2)	148.4 (1.4)	123.1 (2.0)	107.3 (4.0)	11
	C/S DEN	139.6 (10.5)	159.0 (4.6)	156.4 (7.1)	184.4 (8.4)	162.6 (7.9)	198.4 (10.6)	220.0 (13.3)	194.6 (12.2)	209.4 (7.4)	140.2 (4.5)	141.4 (8.4)	5
EYE LEVEL PRESSURE	CONT	59.4	73.4	79.8	73.1	86.3	87.3	71.8	88.3	76.4	99.1	107.3	11
	C/S DEN	89.6	34.0	50.4	34.4	62.6	73.4	45.0	69.6	59.4	90.2	141.4	5
HEART RATE	CONT	131.3 (4.4)	116.9 (5.0)	106.7 (2.9)	121.1 (3.4)	104.9 (4.4)	114.1 (2.1)	126.2 (4.0)	122.3 (6.1)	127.6 (4.9)	122.6 (5.2)	114.3 (3.9)	11
	C/S DEN	107.8 (5.1)	118.0 (8.4)	102.8 (2.2)	118.6 (2.3)	112.8 (2.7)	123.6 (10.5)	120.2 (4.7)	110.4 (4.7)	120.2 (5.1)	176.0 (10.7)	136.4 (10.6)	5




Figure 7




Figure 8




Figure 9

ACM PROFILE
EYE LEVEL B.P.
CONTROL
SUBJECT: DOG A




Figure 10




Figure 11




Figure 12




Figure 13

ACM PROFILE
 EYE LEVEL B.P.
 CAROTID SINUS DENERVATION
 SUBJECT: DOG A

□ NO G-SUIT
 ▨ G-SUIT




Figure 14




Figure 15

TABLE 3

ACM PROFILE
NO G-SUIT
SUBJECT = DOG L

() = SX

+Gz Level		1.0	2.5	2.0	3.0	2.0	4.0	2.5	3.5	2.5	3.0	1.0	STOP	n
CAROTID FLOW	CONT	80.9 (4.1)	62.9 (5.3)	80.1 (5.6)	62.5 (6.4)	98.2 (7.4)	41.6 (5.9)	90.7 (5.7)	66.4 (6.2)	86.7 (7.8)	74.5 (6.4)	125.8 (8.8)	185.0 (7.6)	30
	C/S DEN	86.0 (3.6)	85.9 (7.3)	89.2 (5.4)	91.4 (5.6)	105.4 (6.3)	79.4 (5.7)	113.0 (9.0)	81.8 (5.5)	100.7 (6.2)	86.0 (5.9)	134.6 (6.9)	169.3 (6.5)	27
VENA CAVA FLOW	CONT	94.6 (2.8)	105.0 (2.9)	98.2 (2.9)	88.3 (2.4)	94.3 (3.9)	97.0 (3.3)	96.7 (3.0)	91.6 (4.2)	97.7 (2.7)	91.6 (4.8)	100.8 (5.5)	125.0 (10.4)	30
	C/S DEN													
GENERAL ARTERIAL PRESSURE	CONT													
	C/S DEN	108.5 (4.3)	127.1 (7.6)	130.0 (5.8)	121.0 (9.1)	119.3 (8.9)	130.5 (9.1)	131.6 (9.7)	147.8 (10.3)	133.7 (10.2)	139.8 (7.7)	106.6 (6.7)	127.4 (9.8)	11
EYE LEVEL PRESSURE	CONT													
	C/S DEN	73.5	38.1	59.0	15.0	48.3	0.0	42.6	23.8	44.7	33.8	71.6	127.4	11
HEART RATE	CONT	112.6 (4.5)	175.1 (8.0)	155.4 (8.1)	157.2 (7.2)	148.3 (6.9)	155.5 (7.3)	133.8 (7.4)	156.0 (6.3)	157.8 (9.8)	150.4 (8.1)	188.3 (7.7)	179.2 (6.3)	30
	C/S DEN	118.2 (4.2)	149.9 (10.8)	138.6 (8.6)	155.5 (6.7)	169.4 (11.7)	152.8 (9.4)	182.6 (11.5)	173.4 (11.7)	157.8 (9.5)	151.5 (7.5)	187.7 (5.5)	177.9 (6.8)	27

TABLE 4

ACM PROFILE

G-SUIT

SUBJECT: DOG L

() = SY

+Gz Level	Time (min)										n	
	1.0	2.5	2.0	3.0	2.0	4.0	2.5	3.5	2.5	3.0		1.0
CAROTID FLOW												
CONT												
C/S DEN	94.4 (7.6)	86.2 (9.3)	120.0 (11.0)	106.2 (12.5)	129.8 (13.3)	97.7 (10.2)	126.7 (10.7)	95.8 (12.6)	128.2 (6.5)	117.0 (8.6)	135.7 (10.9)	182.3 (15.6)
VENA CAVA FLOW												
CONT												
C/S DEN												
CENTRAL ARTERIAL PRESSURE												
CONT												
C/S DEN	111.8 (4.1)	147.0 (5.3)	148.7 (6.7)	157.2 (4.6)	155.7 (3.0)	170.0 (1.3)	161.5 (4.5)	174.0 (7.0)	168.5 (5.7)	174.5 (7.6)	122.2 (6.0)	133.2 (4.4)
EYE LEVEL PRESSURE												
CONT												
C/S DEN	73	51	71.7	41.9	78.7	16.0	65.5	39	72.5	59.4	84.2	133.2
HEART RATE												
CONT												
C/S DEN	144.3 (9.4)	130.5 (4.0)	148.5 (11.5)	160.5 (15.0)	145.2 (10.0)	139.2 (18.1)	161.5 (23.5)	171.7 (19.5)	169.2 (11.1)	148.3 (14.0)	180.6 (11.3)	164.4 (22.4)




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21

ACM PROFILE: NO G-SUIT
 EYE LEVEL B.P.
 CONTROL

□ DOG D
 ▨ DOG M




Figure 22




Figure 23




Figure 24




Figure 25

ACM PROFILE: NO G-SUIT
INF. VENA CAVA FLOW
SUBJECT: DOG A




Figure 26




Figure 27




Figure 28




Figure 29




Figure 30




Figure 31




Figure 32

TABLE 7

PULSE PROFILE
NO G-SUIT
SUBJECT: DOG A

() = S \bar{X}

PULSE #	START	MID 1	MIN 1	MID 2	MIN 2	MID 3	MIN 3	MID 4	MIN 4	MID 5	STOP	+10	+20	+30	CONT	n
CAROTID FLOW	101	44.8	123.3	59.5	146.6	55.3		52.5		54.3	116.8	113.0	99.5	93.4	98.0	14
		(6.9)	(13.3)	(4.1)	(13.2)	(5.0)		(4.6)		(6.3)	(13.5)	(10.5)	(4.7)	(5.1)	(6.8)	
C/S DEN																
VERNA CAVA FLOW	106	79.2	123.8	74.0	116.9	68.1	120.5	63.7	121.3	61.5	119.7	93.3	97.6	103.6	98.6	12
		(4.5)	(5.8)	(3.2)	(7.0)	(3.4)	(5.0)	(2.4)	(6.9)	(3.6)	(3.5)	(3.4)	(4.1)	(4.7)	(3.3)	
C/S DEN	103.3	125.0	179.4	118.7	169.6	107.8	174.4	125.6	172.0	115.4	164.3	96.0	100.7	104.5	91.8	6
	(2.6)	(10.4)	(11.2)	(7.9)	(13.2)	(8.3)	(4.0)	(2.9)	(12.0)	(9.5)	(12.5)	(12.0)	(10.7)	(14.1)	(5.8)	
CENTRAL PRESSURE	102.4	114.2	122.3	120.6	123.5	125.0	124.7	123.0	124.1	124.2	114.5	102.1	103.3	102.4	102.2	26
	(0.9)	(3.7)	(4.3)	(4.0)	(3.7)	(3.6)	(2.6)	(4.2)	(4.8)	(4.1)	(2.3)	(1.6)	(1.9)	(1.7)	(1.9)	
C/S DEN	106.5	146.8	164.5	181.2	170.3	188.6	177.7	187.5	179.5	186.2	139.5	105.3	102.7	101.7	99.3	6
	(3.2)	(8.4)	(4.5)	(5.5)	(7.8)	(12.6)	(10.7)	(8.0)	(8.0)	(11.1)	(6.8)	(6.2)	(4.7)	(4.6)	(5.6)	
EYE LEVEL PRESSURE	102	29.2	101.3	35.6	102.5	40.0	103.7	38.0	103.1	39.2	114.5	102.1	103.3	102.4	102.2	26
C/S DEN	106.5	0	122.5	14.2	128.3	21.6	135.7	20.5	137.5	19.2	139.5	105.3	102.7	101.7	99.3	6
HEART RATE	107.3	187.1	131.5	174.3	116.8	162.6	105.3	162.5	121.7	175.7	116.9	114.3	110.9	107.7	99.7	27
	(2.7)	(8.2)	(11.2)	(3.2)	(10.3)	(10.4)	(9.4)	(9.5)	(13.7)	(11.9)	(5.0)	(3.8)	(4.2)	(3.7)	(2.0)	
C/S DEN	104.2	164.7	110.7	124.0	115.3	144.5	109.3	146.5	117.0	131.5	153.5	123.8	121.7	121.5	98.2	6
	(4.2)	(12.2)	(5.0)	(4.5)	(5.3)	(17.6)	(7.0)	(5.0)	(7.7)	(7.1)	(3.5)	(5.6)	(2.4)	(3.7)	(5.2)	

TABLE 8

PULSE PROFILE
G-SUIT
SUBJECT: DOG A

() = S \bar{x}

Pulse #	START	MID 1	MIN 1	MID 2	MIN 2	MID 3	MIN 3	MID 4	MIN 4	MID 5	STOP	+10	+20	-30	CONT	n
CAROTID FLOW	CONT	106.6 (5.6)	58.6 (4.0)	121.0 (13.3)	42.1 (9.9)	108.8 (3.2)	98.0 (6.8)	43.7 (7.4)	103.2 (8.0)	37.1 (8.7)	141.1 (11.5)	135.4 (13.1)	123.1 (9.4)	116.0 (8.8)	110.4 (5.4)	9
	C/S DEN															
VERNA CAVA FLOW	CONT	100.2 (4.7)	103.6 (4.0)	131.3 (4.0)	89.8 (2.0)	116.0 (5.0)	116.0 (2.2)	85.2 (2.8)	115.0 (3.9)	88.6 (1.9)	108.2 (8.8)	86.6 (5.6)	84.6 (7.7)	85.6 (6.7)	96.6 (2.9)	5
	C/S DEN	97.5 (4.5)	95.6 (14.7)	142.8 (11.3)	51.5 (9.4)	108.5 (6.9)	128 (6.3)	45.8 (8.7)	136.8 (5.4)	87.0 (14.1)	146.8 (14.3)	85 (6.3)	77.2 (3.4)	79.5 (4.6)	80.0 (5.6)	6
CENTRAL PULSATORY FLOW	CONT	102.9 (1.3)	139.6 (3.5)	138.9 (3.0)	153.6 (3.4)	139.7 (1.8)	140.2 (2.4)	162.1 (2.8)	141.8 (2.8)	160.7 (3.2)	124.1 (3.0)	109.8 (1.7)	102.5 (3.6)	104.3 (2.0)	99.7 (1.7)	14
	C/S DEN	115.3 (4.6)	239.1 (18.1)	220 (18.5)	257.8 (17.1)	213.5 (14.4)	263 (21.1)	218.6 (17.9)	279.5 (22.5)	222.3 (18.0)	287.3 (27.0)	190.0 (14.5)	118.5 (11.3)	118.5 (11.3)	119.5 (10.7)	6
EYE LEVEL PRESSURE	CONT	102.0	40.6	114.9	55.6	115.7	62.8	114.0	64.1	117.8	62.7	109.2	102.5	104.3	90.6	14
	C/S DEN	115.3	0	155.7	0.3	149.2	5.5	154.3	22.0	159.0	29.8	137.1	118.5	118.5	118.5	6
HEARF RATE	CONT	99.0 (1.2)	167.0 (7.2)	103.5 (5.5)	136.1 (8.6)	112.2 (6.0)	135.7 (7.1)	131.0 (3.5)	116.9 (3.9)	131.0 (4.4)	118.9 (3.9)	110.9 (4.7)	107.3 (3.9)	105.1 (3.9)	102.3 (3.5)	14
	C/S DEN	199.5 (7.1)	197.2 (110)	119.7 (4.4)	189.8 (8.7)	126.7 (6.4)	117.2 (6.6)	124.2 (7.7)	117.6 (5.9)	126.7 (6.4)	142.1 (6.9)	128.5 (2.8)	120.5 (19.8)	102.3 (2.3)	105.2 (5.6)	4

TABLE 9

PULSE PROFILE
 NO G-SUIT
 SUBJECT: DOG L

() = \bar{Sx}

PULSE #	START	MID	MIN	MID	MIN	MID	MIN	MID	MIN	MID	MIN	MID	STOP	+10	+20	+30	CONT	n
C. FLOID FLOW	77.9 (8.9)	61.4 (7.7)	115.7 (13.6)	63.9 (7.6)	128.5 (17.9)	55.8 (13.8)	106.3 (3.8)	67.8 (8.4)	115.9 (7.9)	65.5 (8.8)	160.8 (22.3)	126.8 (26.0)	135.2 (21.6)	113.8 (12.5)	101.5 (13.2)	3		
	C/S DEN	101.5 (2.5)	25.6 (6.6)	86.5 (3.9)	47.5 (5.8)	40.6 (7.5)	99.5 (4.4)	40.1 (7.5)	106.5 (4.5)	40.0 (6.8)	132.5 (6.4)	126.1 (4.6)	118.5 (3.9)	106.9 (4.4)	105.0 (2.3)	18		
VENA CAVA FLOW	102.9 (1.5)	65.0 (11.5)	74.1 (12.1)	88.6 (7.7)	69.0 (11.8)	96.9 (6.1)	51.3 (8.6)	88.1 (10.5)	59.0 (11.6)	88.5 (8.6)	57.4 (7.7)	71.5 (3.5)	79.7 (3.6)	75.4 (4.6)	95.8 (2.2)	3		
	C/S DEN																	
CENTRAL ARTERIAL PRESSURE	96.4 (1.9)	41.6 (5.9)	89.8 (9.3)	116.2 (5.7)	103.0 (3.0)	101.8 (9.7)	100.0 (7.7)	115.4 (7.0)	101.2 (2.0)	126.6 (7.0)	116.6 (7.2)	106.9 (3.3)	97.8 (6.7)	98.2 (1.8)	100.6 (2.6)	18		
	C/S DEN																	
EYE LEVEL PRESSURE	96.4	0	33	0	68	0	47	0	65	0	97	106.0	97.8	98.2	100.6	18		
	C/S DEN																	
HEART RATE	128.4 (19.3)	177.8 (28.1)	160.2 (36.2)	156.2 (12.9)	171.1 (14.5)	172.2 (14.5)	189.5 (5.3)	225.1 (20.9)	211.8 (10.8)	218.0 (10.8)	163.3 (26.9)	161.5 (5.2)	140.2 (9.8)	143.5 (18.1)	114.0 (8.0)	3		
	C/S DEN	95.8 (3.0)	124.8 (7.9)	176.3 (9.7)	168.0 (11.6)	165.5 (10.8)	166.4 (11.7)	171.9 (14.7)	165.0 (13.9)	163.6 (12.6)	168.6 (10.8)	140.5 (6.5)	122.5 (5.0)	116.7 (5.1)	78.3 (5.4)	18		

TABLE 10

PULSE PROFILE
G-SUIT
SUBJECT: DOG L

n=5 ()=SX

Pulse #	START	MID 1	MIN 1	MID 2	MIN 2	MID 3	MIN 3	MID 4	MIN 4	MID 5	STOP	+10	+20	+30	CONT
CAROTID FLOW															
	120.7 (10.4)	103.0 (3.0)	135.8 (9.3)	111.0 (4.7)	129.7 (10.5)	138.2 (8.3)	133.2 (11.6)	73.2 (5.9)	133.2 (11.6)	74.3 (3.2)	169.2 (9.0)	144.3 (8.0)	128.0 (8.9)	115.7 (9.1)	106.3 (6.8)
VENA CAVA FLOW															
CENTRAL ARTERIAL PRESSURE															
	113.2 (12.8)	104.5 (17.7)	139.0 (16.0)	137.5 (9.2)	127.0 (4.7)	139.2 (9.2)	128.0 (5.8)	143.2 (8.9)	145.0 (10.3)	140.0 (8.1)	129.7 (8.4)	131.0 (9.6)	122.8 (7.2)	119.2 (7.6)	106.0 (7.4)
EYE LEVEL PRESSURE															
	113.2	0	104	9.5	92	11.2	93	15.2	110.0	12.0	129.7	131	122	119.2	106
HEART RATE															
	110.0 (4.2)	165.0 (3.2)	141.0 (10.2)	136.5 (16.9)	149.0 (11.2)	154.0 (17.9)	164.0 (12.8)	175.2 (17.4)	177.0 (16.5)	172.0 (16.2)	157.0 (18.9)	119.2 (7.8)	116.7 (4.5)	106.7 (7.7)	87.0 (3.3)

TABLE 12

PULSE PROFILE
 NO G-SUIT
 SUBJECT: DOG M

() = S \bar{x}

PULSE #	START	MID	MIN	MID	MIN	MID	MIN	MID	MIN	MID	MIN	MID	MIN	MID	STOP	+10	+20	+30	CONT n				
CAROTID FLOW		1	1	2	2	3	3	4	4	5													
																					CONT		
VENA CAVA FLOW																							
																						C/S DEN	
CENTRAL ARTERIAL PRESSURE		38.7 (8.8)	86.7 (5.5)	67.0 (3.6)	57.7 (5.2)	65.0 (7.8)	99.3 (11.0)	66.7 (5.5)	97.7 (7.5)	67.3 (1.7)	91.0 (2.1)	89.3 (3.5)	92.7 (6.4)	94.3 (3.5)	99.3 (6.4)	4							
																							C/S DEN
EYE LEVEL PRESSURE		0	51.7	10.0	62.7	8.0	64.3	10.0	62.7	10.0	91	89.3	92.7	94.3	99.3	4							
																							C/S DEN
HEART RATE		209.0 (15.5)	183.5 (22.2)	170.0 (11.0)	146.0 (11.1)	168.3 (12.2)	147.0 (6.0)	158.0 (17.6)	151.3 (12.0)	142.3 (19.8)	136.0 (9.0)	174.7 (7.4)	138.3 (9.7)	123.7 (9.7)	106.3 (15.5)	4							

TABLE 13

SUSTAINED PROFILE

NO G-SUIT

SUBJECT = DOG A

() = Sx

TIME	To	dG=0	To+10'	+0.5'	+1'	+1.5'	+2'	+2.5'	STOP	+10	+20	+30	CONT	n
CAROTID FLOW	CONT	101.5 (1.2)	40.5 (8.3)	36.1 (8.0)	54.3 (5.7)	59.3 (5.9)	61.1 (4.7)	59.7 (6.9)	56.5 (9.2)	125.3 (6.7)	122.5 (6.1)	111.5 (4.7)	107.4 (6.4)	17
	C/S DEN													
VENA CAVA FLOW	CONT	101.1 (3.2)	95.9 (4.4)	104.9 (6.9)	87.6 (6.2)	95.4 (4.8)	100.4 (5.2)	106.1 (8.9)	103.9 (6.6)	100.4 (5.6)	103.3 (5.6)	106.2 (8.6)	95.4 (5.2)	7
	C/S DEN	96.4 (1.3)	96.0 (1.6)	93.2 (2.7)	99.6 (2.4)	98.5 (2.8)	96.4 (2.0)	99.5 (2.3)	98.4 (1.9)	98.4 (3.4)	98.6 (2.0)	98.6 (2.2)	99.7 (1.4)	9
CENTRAL ARTERIAL PRESSURE	CONT	101.7 (0.9)	107.5 (4.2)	129.5 (7.1)	141.5 (6.4)	150.6 (7.8)	151.6 (6.4)	152.5 (5.6)	144.5 (3.4)	104.9 (1.4)	103.2 (1.2)	102.8 (1.9)	104.6 (2.9)	25
	C/S DEN	100.8 (1.3)	111.2 (4.4)	135.5 (7.2)	163.4 (4.9)	176.9 (5.4)	181.4 (3.5)	190.6 (4.4)	201.7 (4.8)	166.7 (5.3)	106.9 (4.1)	110.5 (3.1)	111.7 (3.4)	103.3 (4.6)
EYE LEVEL PRESSURE	CONT	101.7	47.0	69.0	81.0	90.1	91.3	92.0	84.0	104.9	103.2	102.8	104.6	25
	C/S	100.8	10.8	35.1	63.0	76.5	81.0	90.2	101.3	106.9	110.5	111.7	103.3	10
HEART RATE	CONT	104.5 (2.1)	180.9 (4.8)	190.1 (5.1)	153.7 (6.8)	139.0 (6.3)	143.1 (6.6)	151.2 (6.3)	146.4 (7.0)	132.9 (3.7)	126.7 (3.1)	121.0 (3.9)	110.0 (3.2)	25
	C/S	105.4 (3.4)	160.4 (5.5)	170.4 (6.3)	126.2 (7.7)	119.0 (6.4)	128.5 (6.7)	123.7 (5.6)	123.6 (6.9)	157.7 (4.1)	148.9 (7.9)	125.2 (7.5)	103.3 (4.3)	10

TABLE 14

SUSTAINED PROFILE

G-SUIT

SUBJECT: DOG A

() = S \bar{x}

	To	d \bar{G} =0	T ₀ +10"	+5'	+1'	+1.5'	+2'	+2.5'	Stop	+10'	+20'	+30'	Cont	n	
CAROTID FLOW	CONT	100	70.7 (2.7)	68.3 (4.4)	60.2 (6.2)	59.3 (5.1)	58.8 (4.5)	66.8 (4.5)	122.0 (4.0)	112.5 (4.4)	100.5 (6.1)	101.3 (6.7)	93.8 (6.2)	5	
	C/S DEN														
VENA CAVA FLOW	CONT	98.4 (3.3)	107.0 (4.8)	108.2 (1.3)	99.6 (3.1)	97.4 (2.9)	96.2 (3.7)	108.4 (3.0)	101.0 (5.0)	91.6 (5.9)	81.6 (1.8)	78.4 (3.4)	101.3 (1.3)	5	
	C/S DEN	99.7 (3.4)	126.4 (7.2)	146.9 (15.1)	104.0 (4.7)	111.7 (6.4)	98.3 (3.7)	94.3 (7.0)	110.0 (10.5)	192.3 (8.3)	105.3 (3.7)	114.8 (8.7)	114.8 (3.5)	96.5 (5.6)	8
CENTRAL PULSATORY FLOW	CONT	99.5 (0.5)	114.5 (3.1)	129.1 (4.0)	138.6 (2.9)	142 (2.8)	145.3 (3.3)	141.0 (3.7)	145.0 (2.4)	113.0 (1.8)	106.4 (1.8)	104.9 (1.4)	104.6 (1.6)	99.8 (2.6)	10
	C/S DEN	103.3 (3.5)	139.9 (5.9)	165.7 (7.7)	186.4 (7.9)	196.3 (12.1)	204.8 (8.8)	202.3 (7.4)	213.8 (5.2)	156.8 (10.0)	119.2 (3.8)	111.4 (7.5)	112.6 (6.7)	103.0 (2.9)	8
EYE LEVEL PRESSURE	CONT	99.9	53.5	68.1	77.6	81.0	84.3	80.0	84.0	113.0	106.4	104.9	104.6	99.8	10
	C/S DEN	103.3	10.6	36.6	57.3	67.2	75.7	73.2	84.7	156.8	119.2	111.4	112.6	103	8
HEART RATE	CONT	108.7 (2.3)	146.7 (8.7)	147.1 (12.2)	123.7 (3.8)	116.5 (4.7)	113.1 (4.6)	117.5 (5.5)	119.9 (3.7)	116.6 (6.2)	115.5 (7.4)	104.5 (4.3)	103.9 (4.3)	99.6 (6.0)	10
	C/S DEN	109.1 (4.5)	149.0 (7.2)	197.4 (3.5)	139.3 (1.7)	106.3 (4.3)	101.5 (2.7)	104.1 (4.2)	169.2 (8.1)	145.3 (5.0)	115.0 (10.0)	102.1 (2.0)	105.1 (2.5)	98.0 (2.0)	8

TABLE 15

SUSTAINED PROFILE

NO G-SUIT

SUBJECT = DOG L

() = S X

Time	To	dG=0	To+10'	+5'	+1'	+1.5'	+2'	+2.5'	STOP	+10	+20	+30	CONT	n
CAROTID FLOW	CONT	92.4 (3.7)	48.7 (4.6)	59.9 (2.9)	66.7 (4.2)	76.3 (4.7)	72.2 (5.7)	74.3 (4.9)	76.0 (3.4)	137.0 (6.3)	134.3 (6.1)	129.0 (7.7)	100.0 (4.1)	22
	C/S DEN	107.0 (3.5)	69.9 (5.5)	63.9 (4.3)	73.2 (3.2)	74.0 (5.1)	73.4 (4.8)	76.7 (4.7)	72.2 (6.0)	139.8 (6.0)	146.2 (5.1)	131.6 (4.6)	102.0 (3.0)	34
VENA CAVA FLOW	CONT	99.1 (1.0)	91.2 (2.7)	92.1 (3.3)	97.6 (0.9)	96.7 (1.3)	100.0 (0.9)	101.5 (5.7)	99.6 (1.0)	121.8 (3.8)	116.0 (2.8)	110.6 (1.5)	97.8 (0.0)	22
	C/S DEN													
CENTRAL ARTERIAL PRESSURE	CONT													
	C/S DEN	104.2 (4.4)	92.8 (5.3)	87.1 (6.0)	115.1 (5.1)	126.0 (5.4)	137.1 (4.5)	150.7 (6.2)	139.6 (6.3)	126.8 (5.4)	119.9 (3.9)	116.2 (2.3)	103.0 (2.8)	34
EYE LEVEL PRESSURE	CONT													
	C/S DEN	104.2	3.8	0.0	26.1	37.0	48.5	61.7	50.6	126.8	117.9	116.2	103.0	34
HEART RATE	CONT	109.0 (3.6)	166.8 (10.5)	181.1 (12.7)	138.1 (10.9)	147.4 (9.1)	140.3 (5.5)	124.0 (5.4)	122.6 (5.8)	156.1 (5.7)	150.4 (6.7)	132.0 (5.2)	94.5 (2.4)	22
	C/S DEN	104.0 (2.6)	140.2 (6.1)	171.9 (6.1)	168.5 (6.2)	151.0 (5.5)	140.9 (6.5)	131.4 (6.5)	135.6 (4.8)	157.7 (4.7)	145.2 (5.0)	127.1 (4.7)	94.8 (4.6)	34

TABLE 16

SUSTAINED PROFILE

G-SUIT

SUBJECT: DOG L

() = S \bar{x}

Time	To	dG=0	To+10	+5'	+1'	+1.5"	+2'	+2.5'	Stop	+10	+20	+30	Cont	n
CAROTID FLOW	CONT													
	C/S DEN	121.0 (9.8)	73.3 (6.4)	71.7 (7.0)	90.5 (7.0)	95.0 (4.2)	95.8 (4.2)	101.3 (5.3)	94.3 (2.0)	128.3 (9.0)	135.2 (8.4)	114.3 (7.1)	95.7 (5.7)	6
VENA CAVA FLOW	CONT													
	C/S DEN													
CENTRAL ARTERIAL PRESSURE	CONT													
	C/S DEN	100.2 (5.2)	100.8 (9.0)	110.3 (8.0)	133.3 (5.7)	136.0 (2.9)	147.0 (5.6)	145.3 (4.4)	144.1 (8.4)	115.3 (6.7)	108.2 (2.3)	99.3 (3.5)	97.7 (3.9)	6
EYE LEVEL PRESSURE	CONT													
	C/S DEN	100.2	11.8	21.3	44.3	47.0	58.0	56.3	55.7	115.3	108.2	99.3	97.7	6
HEART RATE	CONT													
	C/S DEN	116.3 (2.2)	130.0 (4.6)	122.8 (15.5)	140.0 (14.0)	139.8 (9.2)	119.2 (5.8)	130.5 (101)	152.8 (17.5)	122.8 (10.2)	117.7 (12.9)	137.0 (9.1)	100.7 (4.8)	6

REFERENCES

1. Brown, A. M: Mechanoreceptors in or near the Coronary Arteries.
J Physiol (Lond) 177:203, 1965.
2. Folkow B., Heymans, C., and Neil, E. Integrated Aspects of Cardiovascular Regulation. In, W. F. Hamilton (ed):
Handbook of Physiology: Circulation, Vol. III, Section 3.
American Physiological Society, Washington, D. C., 1963,
pp. 1781-1824.
3. Gauer, O. H. and Henry, J. P. Circulatory Basis of Fluid Volume Control. Physiol Rev 43:423-481, 1963.
4. Gauer, O. H. and Salzman, E. W. Reflex Responses of the Circulation. In, O. H. Gauer and G. D. Zuidema: Gravitational Stress in Aerospace Medicine, Little, Brown & Co., Boston, 1961, pp. 46-51.
5. Gauer, O. H. and Zuidema, G. D. The Physiology of Positive Acceleration. In (their) Gravitational Stress in Aerospace Medicine, Little, Brown & Co., Boston, 1961, pp. 115-133.
6. Frink, R. J. and James, T. N. Intracardiac Route of the Bezold-Jarisch Reflex. Am J Physiol 221: 1464, 1971.
7. Lisander, B. Factors influencing the Autonomic Component of the Defence Reaction. Acta Physiol Scand (Suppl 351) 1970.
8. Doba, N. and Reis, D. J. Role of the Cerebellum and the Vestibular Apparatus in Regulation of Orthostatic Reflexes in the Cat.
Circ Res 34:9, 1974.

-more-

9. Stevens, C. M. The Contribution of Atrial and Carotid Sinus Baroreceptors to the Maintenance of Blood Pressure Under Increased Gravitational Stress. M.S. thesis, University of Southern California, Los Angeles, 1968.
10. Stevens, C. M., Meehan, J. P., and Rader, R. D.: Blood Pressure Measurement with Chronically Implanted Intravascular Transducers. In, E. P. McCutcheon (ed): Chronically Implanted Cardiovascular Instrumentation, Academic Press, New York, 1973, Chap. 26, pp. 235-245.
11. Rader, R. D., Stevens, C. M., and Meehan, J. P. An Interferometric Flow Measurement Technique: A Brief Analysis. IEEE Trans Biomed Eng 21:293-297, 1974.

PUBLICATIONS

1. Stevens, C. M. and Rader, R. D. The Contribution of Vascular Receptors to +Gz Tolerance (Air Force Grant AFOSR 75-2780). In, Review of Air Force Sponsored Basic Research in Environmental and Acceleration Physiology, October 10-12, 1975, at University of California, Santa Barbara, Calif., Air Force Office of Scientific Research, Arlington, Va., 1975.
2. Stevens, C. M., Rader, R. D., and Shaffstall, R. M. The Contribution of Vascular Receptors to +Gz Tolerance. To be presented at the 47th Annual Scientific Meeting of the Aerospace Medical Association, Bal Harbour, Fla., May 10-13, 1976.